Talk
Targeting Neurodegeneration: An AI-guided Visual Biology Approach to discover drug targets for neurodegenerative disease
Dr Ben Bar-Sadeh, Anima Biotech, shared how AI-driven visual biology was applied to ioMotor Neurons with ALS mutations to define complex phenotypic disease signatures, unlocking new insights into disrupted pathways and therapeutic targets in neurodegeneration.
Dr Ben Bar-Sadeh, Anima Biotech, shared how AI-driven visual biology was applied to ioMotor Neurons with ALS mutations to define complex phenotypic disease signatures, unlocking new insights into disrupted pathways and therapeutic targets in neurodegeneration.
Discovering drug targets for neurodegenerative diseases remains a major challenge due to complex, multifactorial biology and limited models. At Anima Biotech, we address this challenge by an AI-guided visual biology approach.
Using bit.bio’s ioMotor Neurons carrying SOD1 and TDP43 ALS mutations, we developed a scalable assay in 384-well plates for high-throughput imaging and analysis. Multiplexed immunofluorescence and automated feature extraction enabled the definition of “PathwayLight” disease signatures - complex phenotypic profiles that reveal disrupted pathways in ALS disease and guide the identification of novel therapeutic targets.
This presentation will highlight assay development strategies, imaging workflows, and the integration of AI, demonstrating how pairing disease-relevant iPSC-derived neurons with visual biology approach provides a powerful strategy for accelerating drug discovery in neurodegenerative diseases.
Using bit.bio’s ioMotor Neurons carrying SOD1 and TDP43 ALS mutations, we developed a scalable assay in 384-well plates for high-throughput imaging and analysis. Multiplexed immunofluorescence and automated feature extraction enabled the definition of “PathwayLight” disease signatures - complex phenotypic profiles that reveal disrupted pathways in ALS disease and guide the identification of novel therapeutic targets.
This presentation will highlight assay development strategies, imaging workflows, and the integration of AI, demonstrating how pairing disease-relevant iPSC-derived neurons with visual biology approach provides a powerful strategy for accelerating drug discovery in neurodegenerative diseases.